MYC and neoplasm: Additional emerging areas include gut microbiota composition, which may modulate ICI efficacy; tumor gene expression signatures (e.g., IFN-γ or MYC/E2F pathways); and epigenomic or proteomic markers that reflect immune resistance or tumor aggression [63,100,103,104,105,106,107].